J Korean Ophthalmol Soc.  2005 Apr;46(4):707-715.

Animal Study of Photodynamic Therapy with Verteporfin in Corneal Neovascularization

Affiliations
  • 1Department of Nursing, Dongkang College, Gwangju, Korea.
  • 2Department of Ophthalmology, Chonnam National University Medical School, Gwangju, Korea. msseo@chonnam.ac.kr
  • 3School of Biological Science and Technology, Chonnam National University, Gwangju, Korea.
  • 4Department of Anatomy, Chonnam National University Medical School, Gwangju, Korea.

Abstract

PURPOSE
To determine the efficacy of photodynamic therapy (PDT) with verteporfin (Visudyne(R), Norvatis Ophthalmics AG, Hettingen, Switzerland), a benzoporphyrin derivative, in the treatment of corneal neo-vascularization (CN) in a rabbit eye model. METHODS: CN was induced by placing instrastromal sutures in the cornea. Two weeks after suturing, verteporfin was administrated intravenously and 1 hour later, the right eye (treated group) was exposed to a laser with a 689 nm wavelength, and the left eye was used as the control. The changes in CN were analyzed using biomicroscopy and optical microscopy in twelve rabbits. RESULTS: The mean percentages of the neovascular area in the control and treated groups were 96.4 +/- 1.9% and 90.3 +/- 3.5% (P=0.009) at three days after the PDT, 88.6 +/- 4.6% and 71.6 +/- 6.2% (P<0.001) at one week, and 76.8 +/- 4.4% and 43.6 +/- 15.1% (P<0.001) at two weeks, respectively. Optical microscopy showed significant differences between the control and treated group in terms of the area and number of CN (P<0.05). CONCLUSIONS: PDT with verteporfin is a safe and effective procedure for regressing CN. However, a further study will be necessary.

Keyword

Corneal neovascularization; Photodynamic therapy; Verteporfin

MeSH Terms

Animals*
Cornea
Corneal Neovascularization*
Microscopy
Photochemotherapy*
Rabbits
Sutures
Full Text Links
  • JKOS
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr